



THE EBMT REGISTRY: 2025 ACHIEVEMENTS & MILESTONES

Annelot van Amerongen¹, Alina Kuliesh¹, Igor Ariz Extreme², Fernando Cid Samper², Laura Moreno Sabaté², Nikolaos Glentis¹, Eden Tsehay Abera², Hendrikus Bernard Bouwman¹, Nadiia Dyba², Ignacio García Sánchez-Migallon¹

¹ EBMT, Leiden, Netherlands (the)

² EBMT, Barcelona, Spain

The EBMT Registry

In October 2025 EBMT achieved ISO/IEC 27001:2022 certification, demonstrating the EBMT Registry adheres to the international standards for safely storing and processing data.

The EBMT Registry itself had 7 releases that introduced new functionalities and overall improvements. With the addition of summary fields on patients, an audit trail and export functionality, it has been made easier for users to quickly access any data they need. Several technical updates were made for improved system and study management. MicroStrategy, the exporting tool launched in 2024, has been migrated to an optimised cloud environment with improved performance and additional functionality.

The Registry Unit acquired one new IT analyst in 2025, who works from the Barcelona office. The Registry Unit now consists of 1 manager, 1 IT team lead, 1 data operations team lead, 1 data management specialist, 4 IT analysts, 3 data managers, and 1 data steward. The team is located in Spain and the Netherlands.



Figure 1. EBMT Registry wrapped of all activity in the EBMT Registry by all users in 2025




Figure 2. Curve showing the growth of patient counts in the EBMT Registry since go-live

Data reporting

In 2025, 37.329 new patients were registered in the EBMT Registry. 18.875 new allogeneic HCTs were reported, 18.504 autologous HCTs, and 4.757 CAR-Ts. These trends are consistent with previous years.

In total, the EBMT Registry had 804.745 patients on December 31, 2025. Patients can be classified into 13 diagnosis classifications.

Diagnosis classification	Count of diagnosis events
Acute leukaemia	218.155
Autoimmune disease	5.155
Bone Marrow Failure incl. Aplastic Aneamia	25.550
Chronic leukaemia	34.296
Hemoglobinopathy	10.562
Inborn Errors	13.520
Lymphoma	220.622
Myelodysplastic syndrome	30.438
Myelodysplastic/myeloproliferative disease	7.422
Myeloproliferative disorder	12.904
Other Diagnosis	2.669
Plasma cell neoplasm	212.450
Solid tumour	51.864
Total diagnosis events	845.607

Table 1. Count of diagnosis events in the EBMT Registry as of December 31, 2025.

Data collection & exporting

During 2025, 7 new dashboards were added to the Library, with more to come during 2026!

In March 2025, updated data collection forms were released. The updates performed consists on minor updates and quality of life improvements together with updates to Disease status classifications, among others



Figure 3. Icons of new reports in the EBMT Strategy library

2026 plans

In 2026, the Registry Unit's goals are centred around stability and consolidation of good practices, implementing strong data governance policies together with data quality procedures to ensure the data provided by EBMT's members can be used to support EBMT's mission of saving and improving the lives of patients with blood-related disorders. Updated data collection forms are being developed with a planned launch in April 2026, after the annual meeting. The aim is to focus on the important variables of the core dataset and moving several variables to the extended dataset. This will allow focussing on EBMT studies and reducing the workload of the centres reporting data.